SC
SPRY icon

Stephens Consulting’s ARS Pharmaceuticals SPRY Stock Holding History

Stephens Consulting’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$378 – 1890
2025
Q1 		$378 Buy
+30
New +$361 ﹤0.01% 1150

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Stephens Consulting's SPRY Position: Q2 2025 in Review

Stephens Consulting sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 30 shares — an estimated $378 sold.

Stephens Consulting first reported a position in SPRY in Q1 2025 and held it in 1 quarter. The position peaked at $378 in Q1 2025. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • Stephens Consulting reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 30 ARS Pharmaceuticals shares in Q2 2025, an estimated $378.
  • Stephens Consulting first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's ARS Pharmaceuticals position peaked at $378 in Q1 2025.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.